Despite the success of these new therapies, not all people respond the same. Cancer therapies may respond exceptionally well or have little or no effect, depending on a number of factors including race or ethnicity. This varying response will continue to grow as new drugs are genetically requiring greater male diversity in treatment options. Since Black men have historically been underrepresented in prostate cancer clinical trials, a more concerted effort is needed to increase their participation in prostate cancer clinical trials.
To address this need, PHEN has created Clinical Trial Learning Sessions. In conjunction with leading cancer medical centers, PHEN brings Black men and clinical trial doctors together so that both understand each other's expectations from the clinical trial and to develop a relationship with these well-known cancer centers.
PHEN's first virtual learning session of 2023 is on March 2nd at 6:00 PM EST with Johns Hopkins. During this session, men will learn about current prostate cancer clinical trials, ask the doctors who are running these trials questions and discuss their concerns. The clinical trials, which will be discussed, are found below.